Response to Comment on “Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer’s Disease: Progress and Challenges”
The Senior Care Pharmacist · 01.08.2026 · 41 (5) · 159-160
DOI: 10.4140/tcp.n.2026.159 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Senior Care Pharmacist, erschienen am 01.08.2026. Verfasst von Muhammad A Qudoos und 1 weiteren Autor:innen. Beteiligte Einrichtung: 1Ambulatory Care Pharmacy, Samaritan Lebanon Community Hospital, Lebanon, OR.
Themen: Demenz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- 1Ambulatory Care Pharmacy, Samaritan Lebanon Community Hospital, Lebanon, OR.
- 2West Virginia University School of Pharmacy, Charleston, WV.
Zitieren
APA
Qudoos, M. A., & Elliott, D. P. (2026). Response to Comment on “Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer’s Disease: Progress and Challenges”. The Senior Care Pharmacist, 41(5), 159-160. https://doi.org/10.4140/tcp.n.2026.159
Vancouver
Qudoos MA, Elliott DP. Response to Comment on “Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer’s Disease: Progress and Challenges”. The Senior Care Pharmacist. 2026;41(5):159-160. doi:10.4140/tcp.n.2026.159
BibTeX
@article{Qudoos2026,
author = {Qudoos, Muhammad A and Elliott, David P},
title = {Response to Comment on “Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer’s Disease: Progress and Challenges”},
journal = {The Senior Care Pharmacist},
year = {2026},
volume = {41},
number = {5},
pages = {159--160},
doi = {10.4140/tcp.n.2026.159}
}
EUVIMED